Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
1.63
USD
|
+2.52%
|
|
+0.31%
|
-38.26%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
365
|
378.8
|
359.2
|
122.7
|
119.1
|
79.29
|
-
|
-
|
Enterprise Value (EV)
1 |
365
|
293.9
|
294.8
|
122.7
|
119.1
|
79.29
|
79.29
|
79.29
|
P/E ratio
|
-9.56
x
|
-8.02
x
|
-8.02
x
|
-1.91
x
|
-2.38
x
|
-1.63
x
|
-1.62
x
|
-1.55
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
106
x
|
120
x
|
24
x
|
98.5
x
|
21.7
x
|
7.52
x
|
5.4
x
|
4.08
x
|
EV / Revenue
|
106
x
|
120
x
|
24
x
|
98.5
x
|
21.7
x
|
7.52
x
|
5.4
x
|
4.08
x
|
EV / EBITDA
|
-
|
-8,611,598
x
|
-8,461,223
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-11,447,277
x
|
-9,036,839
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
22,994
|
30,278
|
31,761
|
43,043
|
45,123
|
48,643
|
-
|
-
|
Reference price
2 |
15.88
|
12.51
|
11.31
|
2.850
|
2.640
|
1.630
|
1.630
|
1.630
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/16/22
|
3/21/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3.458
|
3.154
|
14.94
|
1.245
|
5.49
|
10.54
|
14.69
|
19.45
|
EBITDA
|
-
|
-43.99
|
-42.45
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-36.77
|
-45.04
|
-43.71
|
-53.22
|
-52.15
|
-52.64
|
-63.87
|
-71.21
|
Operating Margin
|
-1,063.21%
|
-1,427.96%
|
-292.56%
|
-4,274.3%
|
-949.89%
|
-499.37%
|
-434.71%
|
-366.09%
|
Earnings before Tax (EBT)
1 |
-36.29
|
-44.58
|
-43.67
|
-53.01
|
-50.73
|
-51.75
|
-62.74
|
-69.98
|
Net income
1 |
-36.7
|
-44.78
|
-44.16
|
-53.01
|
-50.73
|
-51.75
|
-62.74
|
-69.98
|
Net margin
|
-1,061.18%
|
-1,419.79%
|
-295.56%
|
-4,257.08%
|
-924.1%
|
-490.91%
|
-427.03%
|
-359.72%
|
EPS
2 |
-1.660
|
-1.560
|
-1.410
|
-1.490
|
-1.110
|
-1.000
|
-1.004
|
-1.053
|
Free Cash Flow
|
-
|
-33.09
|
-39.75
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-1,049.01%
|
-266.04%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/16/22
|
3/21/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
8.254
|
1
|
0.026
|
0.068
|
0.1512
|
0.187
|
1.382
|
2.1
|
1.821
|
1.717
|
1.289
|
1.293
|
6.248
|
1.402
|
1.446
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.893
|
-14.24
|
-13.09
|
-11.03
|
-14.87
|
-13.38
|
-13.52
|
-11.42
|
-13.83
|
-12.67
|
-13.73
|
-15.07
|
-11.17
|
-17.81
|
-18.82
|
Operating Margin
|
-95.62%
|
-1,423.8%
|
-50,346.15%
|
-16,222.06%
|
-9,829.93%
|
-7,155.08%
|
-978.08%
|
-543.76%
|
-759.58%
|
-737.8%
|
-1,064.86%
|
-1,165.52%
|
-178.86%
|
-1,270.57%
|
-1,301.04%
|
Earnings before Tax (EBT)
1 |
-7.889
|
-14.26
|
-13.21
|
-10.96
|
-14.59
|
-13.11
|
-13.18
|
-11
|
-13.43
|
-12.35
|
-13.58
|
-14.84
|
-11
|
-17.83
|
-18.87
|
Net income
1 |
-8.384
|
-14.26
|
-13.21
|
-10.96
|
-14.59
|
-13.11
|
-13.18
|
-11
|
-13.43
|
-12.35
|
-13.58
|
-14.84
|
-11
|
-17.83
|
-18.87
|
Net margin
|
-101.57%
|
-1,425.5%
|
-50,800%
|
-16,110.29%
|
-9,649.13%
|
-7,010.16%
|
-954.05%
|
-524.05%
|
-737.73%
|
-719.1%
|
-1,053.41%
|
-1,147.73%
|
-176.07%
|
-1,272.35%
|
-1,304.49%
|
EPS
2 |
-0.2500
|
-0.4400
|
-0.3700
|
-0.3100
|
-0.3800
|
-0.2900
|
-0.2900
|
-0.2400
|
-0.2900
|
-0.2500
|
-0.2725
|
-0.2575
|
-0.2075
|
-0.3500
|
-0.3550
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/22
|
5/10/22
|
8/4/22
|
11/14/22
|
3/21/23
|
5/9/23
|
8/8/23
|
11/3/23
|
3/28/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
84.9
|
64.4
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-33.1
|
-39.8
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.05
|
-
|
0.91
|
-
|
-
|
1.34
|
1.79
|
2.22
|
Capex / Sales
|
1.34%
|
-
|
6.11%
|
-
|
-
|
12.7%
|
12.2%
|
11.4%
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/16/22
|
3/21/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
1.63
USD Average target price
9.4
USD Spread / Average Target +476.69% Consensus |
1st Jan change
|
Capi.
|
---|
| -38.26% | 79.29M | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|